Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
Remains on track to provide regulatory update on registrational trial plans with NGN-401 for Rett syndrome in the first half of 2025Continues to expect to share additional interim clinical data from NGN-401 Phase 1/2 trial in the second half of 2025Received PRIME designation for NGN-401 from the European Medicines AgencyCash runway into the second half of 2027 NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.“We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NGNE) Stock [Seeking Alpha]Seeking Alpha
- Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates [Yahoo! Finance]Yahoo! Finance
- MAAST DIGITAL Unveils AI-Powered ERMA Evaluate™: A Revolutionary Platform Set to Transform the Traditional Medical, Legal and Regulatory Review Process for Life Science Companies [Yahoo! Finance]Yahoo! Finance
NGNE
Earnings
- 11/18/24 - Beat
NGNE
Sec Filings
- 3/28/25 - Form 4
- 3/28/25 - Form 4
- 3/28/25 - Form 4
- NGNE's page on the SEC website